Business Context and Reporting Period
This Form 8-K Current Report was filed by Karyopharm Therapeutics Inc. on August 8, 2014, covering events occurring on August 6 and August 7, 2014. The filing addresses significant changes in executive leadership, specifically the appointment of a new Chief Financial Officer and the departure of the former Senior Vice President of Finance and Administration.
Key Financial Metrics and Compensation
This filing does not report operational financial metrics such as revenue, profit, cash flow, or debt levels. It details specific compensation and severance arrangements for executive officers:
- Justin Renz (New CFO): Annual base salary of $345,000; annual bonus target of 35% of base salary; incentive stock option for 245,000 shares; severance of 6 months' salary for termination without cause prior to a Change in Control, or 9 months' salary if within one year following a Change in Control.
- Paul Brannelly (Departing SVP): Consulting fee capped at $75,000 (rate of $350/hour); severance payments totaling $142,500 paid over six months; potential performance payment up to $71,250; continued vesting of unvested stock options during the consulting term.
Material Changes Versus Prior Period
The primary material change reported is the transition of financial leadership effective August 2014:
- Appointment: Justin Renz was appointed Executive Vice President and Chief Financial Officer, effective August 18, 2014.
- Departure: Paul Brannelly stepped down as Senior Vice President, Finance and Administration and Treasurer, effective August 7, 2014.
- Transition Arrangement: Mr. Brannelly entered into a consulting agreement to provide advisory services until November 1, 2014, to facilitate the transition.
Outlook, Risks, and Unusual Items
The filing does not provide forward-looking guidance, market outlook, or general risk factors. The primary contingencies relate to the employment agreements:
- Severance Triggers: Mr. Renz's severance is contingent upon termination without Cause or resignation for Good Reason, with enhanced benefits if these events occur within one year of a Change in Control.
- Performance Discretion: Mr. Brannelly's potential $71,250 payment is subject to the sole discretion of the Compensation Committee based on satisfactory performance under the consulting agreement.
- Stock Repurchase Waiver: The Company agreed not to assert repurchase rights regarding 63,636 shares of Common Stock held by Mr. Brannelly.
Investor Verification Checklist
- Verify the effective start date of Justin Renz as CFO (August 18, 2014) and his prior experience at Zalicus Inc.
- Confirm the total potential cash outflow for Mr. Brannelly's separation, including the $142,500 severance, up to $75,000 in consulting fees, and up to $71,250 in performance payments.
- Review the attached Exhibit 10.1 (Offer Letter) and Exhibit 10.3 (Separation Agreement) for full legal terms regarding stock options and termination definitions.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for revenue and liquidity metrics.